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Abstract
Background: Endothelial nitric oxide synthase produces nitric oxide which is involved in many
physiologic regulatory functions. Variable number of tandem repeats in intron 4 of endothelial nitric
oxide synthase gene are reported to be associated with blood pressure regulation. Nitric oxide is
involved in regulation of cardiomyocyte genes but it is not known If endothelial nitric oxide
synthase 4 gene polymorphisms are related with left ventricular hypertrophy. We studied
endothelial nitric oxide synthase 4a/b allele status in hypertensive and normotensive patients and
echocardiographic parameters in a subgroup of hypertensive group.
Methods: We performed a case-control study involving 110 Turkish hypertensive patients and 87
controls. All subjects were genotyped for endothelial nitric oxide synthase 4a/b polymorphism.
Echocardiographic measurements were obtained in 94 of the hypertensive patients.
Results: Endothelial nitric oxide synthase 4a/b genotype frequencies were 6.4%, 23.6%, 70% in
hypertensives and 1.1%, 18.4%, 80.5% in controls for a/a, a/b, b/b, respectively. Left ventricular
dimensions, mass and diastolic indices were not different across endothelial nitric oxide synthase
4 genotypes. Patients with 4a/a genotype had higher interventricular septal thickness than the other
group; 14.83(1.6), 11.91(1.51), 12.21(1.56) for a/a, a/b, b/b, respectively and p = 0.0001.
Conclusion: Endothelial nitric oxide synthase 4a/b gene polymorphism is not associated with
hypertension in Turkish patients. 4a/a genotype was associated with higher interventricular septal
thickness in hypertensive patients.
Background
Endothelial nitric oxide synthase (ecNOS; NOS3) pro-
duces nitric oxide (NO) from L-arginine. NO has diverse
physiologic regulatory functions and is involved in
smooth muscle relaxation, inhibition of platelet aggrega-
tion, immune regulation, neurotransmission and blood
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pressure regulation [1-3]. NO deficiency induces vascular
and cardiac hypertrophy and inhibition of ecNOS reduces
coronary flow and raises blood pressure [4,5]. NO regu-
lates expression of genes in cardiac myocytes that are
important in cardiac hypertrophy and failure. In cDNA
expression array analysis 10 genes out of the 1176
endothelial genes were consistently up- or downregulated
by NO [6]. ecNOS is encoded by a gene located on chro-
mosome 7q35–36, expressed in endothelium. Some
ecNOS alleles affect nitric oxide levels and cardiovascular
system. There are two alleles identified in intron 4 of the
ecNOS gene. The larger allele, 4b, consists of five tandem
27-bp repeats (variable number of tandem repeats-VNTR)
and smaller one, 4a, has four repeats [7,8]. An association
of the 4a allele of the ecNOS gene with coronary artery
disease and renal disease was reported [8-11]. The intron
4 VNTR polymorphism was associated with altered
plasma NO levels and variations in plasma nitrite and
nitrate levels [9,12]. However, conflicting data have
appeared in the literature concerning the association
between this variant and hypertension. In fact, the intron
4 VNTR polymorphisms were associated with hyperten-
sion in one Japanese study but other studies found no
association [13-15]. Interethnic differences in NO-medi-
ated vasodilation may result from disproportionate distri-
bution of ecNOS variants in ethnic groups. Interethnic
differences in ecNOS variants may result in a higher inci-
dence and severity of hypertension in African-Americans.
Genetic determinants underlying interethnic differences
in drug response can help to predict the drug effects and
improve therapy [16-18]. To the best of our knowledge
there is no data about ecNOS4a/b polymorphism in Turk-
ish hypertensive patients.
In our study we examined ecNOS gene intron 4 VNRT pol-
ymorphism in hypertensive and normotensive Turkish
patients. Echocardiographic examinations were obtained
in a subgroup of hypertensive patients and relationship
between echocardiographic left ventricular indices and
ecNOS intron 4 VNRT polymorphism determined.
Methods
Study population
A total of 110 hypertensive patients who were under drug
treatment were included into the study from Istanbul
School of Medicine Cardiology Department. Blood sam-
ples were obtained from 90 healthy individuals applying
to outpatient clinic of internal medicine with nonspecific
complaints. All of the hypertensive patients were on one
or more antihypertensive drugs. Patients were all in mild
to moderate hypertension group. Hypertension control
was assessed by the cardiologist in the outpatient clinic
and all patients were reported to have a well controlled
hypertension. DNA for analysis was not available for three
subjects in control group. Echocardiographic measure-
ments were obtained in 94 hypertensive patients. Patients
who had rheumatic valvular disease, myocardial infarc-
tion, renal disease and secondary hypertension were not
enrolled into the study. Ethics committee approval and
informed consent was obtained from all patients. Anthro-
pometric measurements and clinical parameters were
determined by a questionnaire based study. Echocardio-
graphic and genotype data were obtained by independent
observers unaware of the other test results.
Genotyping
Detection of eNOS polymorphism
ecNOS4a/b genotypes were determined by polymerase
chain reaction (PCR) using oligonucleotide primers
(sense: 5'-AGGCCCTATGGTAGTGCCTTT-3' ; antisense,
5'-TCTCTTAGTGCTGTGGTCAT-3' Prizma Laboratory
Products Industry and Trade Co. LTD., Istanbul, TR) that
flank the region of the 27 bp direct repeat in intron 4 as
described previously with minor modifications [11].
Reactions were performed in a total volume of 50 μL con-
taining 500 ng genomic DNA, 10 pmol of each primer,
0.2 mM dNTP, 0.5 U Taq DNA polymerase, 5 μL PCR
buffer (500 mmol/L KCL, 100 mmol tri-hidroksimetil-
aminometan chloride and 0.8% Nonidet P40). The ther-
mocycling (Perkin Elmer Cetus, DNA Thermal Cycler 480,
USA and Eppendorf Mastercycler Personal 5332, Ger-
many) procedure consisted of initial denaturation at 94°
for 5 min, 35 cycles of denaturation for 94° for 1 min,
annealing at 55° for 1 min, extension at 72° for 1 min.
The PCR products were analyzed using 3% agarose gel
electrophoresis and visualized by ethidium bromide
staining. The large allele, ecNOS4b, contains 5 tandem 27
bp repeat and the smaller allele, ecNOS4a, contains 4
repeats. The size of the PCR products were 393 bp and 420
bp for the ecNOS4a and ecNOS4b alleles, respectively.
Echocardiography
All patients were studied by M-mode echocardiography to
determine left ventricular size (left ventricular end diasto-
lic diameter- LVED, left ventricular end systolic diameter-
LVES, interventricular septum-IVS and posterior wall
thickness-PW) by three expert sonographers with two
recorders (Vingmed System V and Vivid III, General Elec-
tric). Pulsed doppler velocimetry was used to determine
peak early (E) and late atrial (A) diastolic transmitral
velocities. Penn convention criteria were applied for
measurement of left ventricular dimension and calcula-
tion of LV mass-LVM [19]. Left ventricular mass index-
LVMI was calculated by indexation of LVM to body surface
area. LV ejection fraction was calculated according to the
modified Simpson formula [20].
Statistical analysis
Data were analyzed using SPSS for Windows release 7.5.1.
Percentages were compared by X2 analysis. According toCardiovascular Ultrasound 2006, 4:33 http://www.cardiovascularultrasound.com/content/4/1/33
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ecNOS4a/b allele status, continuous data were compared
with the use of ANOVA. Effects of NOS4a/b allele status
on LV mass index (obtained by indexation of LVM to
body surface area), LVED/m2 (LVED indexed to body sur-
face area), LVES/m2 (LVES indexed to body surface area)
LV ejection fraction (EFM), fractional shortening (FS),
diastolic E and A velocities were examined with multiple
linear regression analysis after adjustment for age, gender,
body mass index, atrial fibrillation (AF), diabetes mellitus
(DM) and hypertension treatment status (HTTx). LV
hypertrophy (LVH) was defined as an LV mass index of >
134 g/m2 in men or > 110 g/m2 in women. Left ventricular
hypertrophy (absence or presence) was analyzed as a cat-
egorical variable by logistic regression. Continuous data
are summarized as mean ± SD or as median. All tests were
two sided, and a P value of less than 0.05 was considered
to indicate statistical significance
Results
Genotype frequencies
We genotyped 110 hypertensive patients and 87 healthy
controls for the ecNOS 4a/b gene polymorphism. Clinical
characteristics of the study group are summerized in Table
1. There was no significant differences between groups
with respect to sex distribution and presence of diabetes
mellitus. Control group subjects were younger than
hypertensive patients, 40.53(15.83) vs 59.41(10.14) and
p = 0.0001. Smoking was more frequent in control group,
34.5 vs 21.8 and p = 0.048.
The distribution of genotypes and allele frequencies were
compared between patients and controls in Table 2. The
genotype frequencies were in agreement with Hardy-
Weinberg equilibrium. ecNOS4a/b genotype frequencies
in hypertensives were 6.4%, 23.6%, 70% for aa, ab, bb,
respectively and 1.1%, 18.4%, 80.5% for aa, ab, bb,
respectively in control group. Genotype frequencies were
not statistically different between groups (X2 = 4.59, p =
0.10).
Echocardiographic measurements
Echocardiographic examinations were obtained from 94
patients in hypertensive group. Clinical characteristics of
the hypertensive subgroup of patients according to
ecNOS4 allele status are listed in Table 3. Age, sex, preva-
lence of smoking, diabetes mellitus, atrial fibrillation,
duration of hypertension were not statistically different
between three groups. All patients were receiving antihy-
pertensive therapy and none of the patients consumed
alcohol.
Echocardiographic measurements are listed in Table 4.
Left ventricular end systolic and end diastolic dimensions
indexed to body surface area, posterior wall thickness, left
ventricular ejection fraction, fractional shortening, left
ventricular mass index, early diastolic transmitral peak
velocity (E), late diastolic transmitral peak velocity and
left atrial sizes showed no statistically significant differ-
ences across aa, ab or bb genotypes. Interventricular septal
thickness was 14.83(1.6), 11.91(1.51), 12.21(1.56) for
aa, ab, bb, respectively and p = 0.0001. Patients with 4a/a
genotype had higher septal thickness than the other
groups and difference was statistically significant. Left
ventricular hypertrophy was present in 75.3% of the study
population. Left ventricular hypertropy percentages were
not statistically different across ecNOS4 genotypes.
Discussion
The results of our study indicate that ecNOS4a/b poly-
morphism is not associated with with hypertension, left
ventricular dimension or mass but is associated with inter-
Table 3: Clinical characteristics of hypertensive patients 
included in echocardiographic substudy
Characteristic ecNOS4a/b polymorphism
a/a
n = 6
a/b
n = 22
b/b
n = 66
p
Sex, M/F 1/5 8/14 26/40 X2 = 1.22
p = 0.54
Age, y 59(10.06) 62.14(9.21) 58.28 (10.639) 0.30
DM, % 33.3 18.2 15.2 0.51
Smoking, % 16.6 22.7 19.7 0.93
Alcohol, % 0 0 0 --
AF, % 33.3 9.1 6.1 0.70
HT age 5.83(2.04) 6.59(3.23) 9.02(7.4) 0.20
HT Tx, % 100 100 100 --
DM: diabetes mellitus, AF: atrial fibrillation, HT age: duration of 
hypertension, HT Tx: treatment for hypertension.
Table 1: Clinical characteristics of the study group
Characteristic HT
n = 110
NT
n = 87
P
Age, year 59.41(10.14) 40.53(15.83) 0.0001
Sex, M/F % 39.1/60.9 47.8/52.2 0.21
Smoking, % 21.8 34.5 0.048
Diabetes Mellitus, % 16.4 5.6 0.17
HT: hypertensive subjects, NT: healthy controls
Table 2: ecNOS4a/b genotype distribution in hypertensive 
patients and controls
ecNOS4a/b genotypes HT NT
a/a, n, (%) 7 (6.4) 1 (1.1)
a/b, n, (%) 26 (23.6) 16 (18.4)
b/b, n, (%) 77 (70) 70 (80.5)
Total, n, (%) 110 (100) 87 (100)
X2 = 4.59 P = 0.10
HT: hypertensive subjects, NT: healthy controlsCardiovascular Ultrasound 2006, 4:33 http://www.cardiovascularultrasound.com/content/4/1/33
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ventricular septal thickness. To our knowledge there was
no previous study about relation of ecNOS4a/b polymor-
phism with hypertension in Turkish population. Most of
the previous studies about ecNOS4a/b polymorphism
and hypertension in literature are negative association
studies and we examined whether there is any positive
association in our study population [10,15]. A previous
Turkish study showed that patients with myocardial inf-
arction had higher frequency of a/a genotype, 4.3% [21].
In the study genotype distribution in normal population
was 0.6% for a/a, 18% for a/b and 81.4% for the b/b gen-
otype. There was no statistically significant difference in
ecNOS4a/b allele percentages between cases and controls.
The defect in NO production in hypertension could
involve a gene other than ecNOS4. In fact, discrepancies
in association studies may also result from consideration
limited to only one polymorphism rather than combina-
tions of polymorphisms. In particular, recent data suggest
that individual eNOS genotypes are not reliable markers
of risk for developing hypertension, but study of eNOS
haplotypes may provide much more appropriate informa-
tion [22,23].
In 94 of the hypertensive patients we obtained echocardi-
ographic measurements to see whether any subgroup of
ecNOS4a/b polymorphism is associated with left ven-
tricular dimensions or mass. Although there are previous
animal studies about effect of NO on vascular and cardiac
myocytes, relation of ecNOS4a/b polymorphism with left
ventricular hypertrophy and function in hypertension was
not examined in humans previously [13]. In a previous
human study ecNOS Glu298Asp polymorphism was not
found to be related with blood pressure, left ventricular
mass or carotid intima media thickness [24]. In another
study three polymorphisms including -922A>G, intron
4VNTR, and Glu298Asp of the eNOS gene were investi-
gated and no associations between single polymorphisms
or haplotypes of the ecNOS gene and systolic blood pres-
sure or left ventricular mass were found [25].
In our hypertensive subgroup of patients left ventricular
dimensions, left ventricular mass index and left ventricu-
lar diastolic indices were not different in ecNOS4a/b sub-
groups. On the other hand interventricular septal
thickness was higher in a/a genotype; 14.83(1.69) for a/a,
11.91(1.51) for a/b, 12.21(1.56) for bb and p = 0.0001.
Although all patients were under hypertension treatment,
septal hypertrophy in a/a genotypes may be due to higher
susceptibility of those patients for hypertrophy. Relation
of ecNOS4a/b polymorphism and left ventricular hyper-
trophy needs to be determined in untreated hypertensive
patients to see if there is a similar association in untreated
patients.
Limitations of our study are that all study patients were
treated with different drugs and a detailed subgroup anal-
ysis can not be done due to small sample size. Echocardi-
ographic measurements may be suboptimal when
compared to toher methods like magnetic resonance
imaging.
In conclusion ecNOS4a/b polymorphism is not associ-
ated with hypertension in Turkish population. Echocardi-
ographic left ventricular dimensions and left ventricular
mass are not associated with ecNOS4a/b polymorphism
in treated hypertensive patients. Interventricular septal
thickness is increased in patients with ecNOS4 a/a geno-
type. Relation of ecNOS4a/b genotype and left ventricular
Table 4: Echocardiographic measurements and ecNOS4a/b genotypes in hypertensive patients included in echocardiographic 
substudy
Variable ecNOS4a/b polymorphism
a/a a/b b/b p
LVEDD 27.22(2.93) 27.72(4.53) 27.65(5.03) 0.93
LVESD 17.44(3.25) 18.61(5.18) 18.32(5.26) 0.89
IVS, mm 14.83(1.6) 11.91(1.51) 12.21(1.56) 0.0001
PW, mm 12.17(1.94) 10.95(1.43) 10.74(1.51) 0.92
LV EF, % 65.33(8.45) 60.82(14.61) 61.97(14.33) 0.78
LV FS, % 36.17(7.11) 33.14(10.22) 34.06(9.69) 0.78
LVMI, g/m2 173.5(27.29) 141.77(37.31) 151.78(56.32) 0.39
LVH, % 100 77.3 72.3 X2 = 2.23
p = 0.31
E, cm/s 57(26.06) 64.53(21.06) 72.05(24.3) 0.33
A, cm/s 96(16.64) 77.94(13.75) 80.93(26.77) 0.49
LA size, mm 43(12.81) 39.5(6.26) 37.26(5.42) 0.56
LVEDD: left ventricular end-diastolic dimension mm/m2, LVESD: left ventricular end-systolic dimension mm/m2, IVS: interventricular septal 
thickness mm/m2, PW: posterior wall thickness mm/m2, LV FS: left ventricular fractional shortening, LVMI: left ventricular mass index (Penn 
formula), E: early diastolic transmitral peak velocity, A: late diastolic transmitral peak velocity, LA: left atrium size mm.Cardiovascular Ultrasound 2006, 4:33 http://www.cardiovascularultrasound.com/content/4/1/33
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hypertrophy needs to be determined in untreated hyper-
tensive patients. If genetic factors determining left ven-
tricular hypertrophy and dilatation in hypertensive
patients are determined, those patients under greater risk
can be treated more aggressively and with drugs suitable
to genetic markers.
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